Fahim Masum

Fahim Masum

Auto-generated profile, based on publicly available information

Fahim Masum

Department of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2019 in Lab on a Chip
Verified
Journal Article
Closed access
PDF file
SKSeunggyu Kim
Seunggyu Kim
FMFahim Masum
Fahim Masum
JKJu-Kang Kim
Ju-Kang Kim
HCHyun Jung Chung
Hyun Jung Chung
JJJessie Jeon
Jessie Jeon
Combinatory therapy using two or more kinds of antibiotics is attracting considerable attention for inhibiting multi-drug resistant pathogenic bacteria. Although the therapy mostly leads to more powerful antimicrobial effects than using a single antibiotic (synergy), interference may arise from certain antibiotic combinations, resulting in the antimicrobial effect being suppressed (antagonism). Here, we present a microfluidic-based phenotypic screening chip to investigate combinatory antibiotic effects by automatically generating two orthogonal concentration gradients on a bacteria-trapping agarose gel. Computational simulations and fluorescence experiments together verify the simultaneous establishment of 121 concentration combinations, facilitating on-chip drug testing with stability and efficiency. Against Gram-negative bacteria, Pseudomonas aeruginosa, our chip allows the measurement of phenotypic growth levels, and enables various types of analyses for all antibiotic pairs to be conducted in 7 h. Furthermore, by providing a specific amount of susceptibility data, our chip enables the two reference models, Loewe additivity and Bliss independence, to be implemented, which classify the antibiotic interaction types into synergy or antagonism. These results suggest the efficacy of our chip as a cell-based drug screening platform for exploring the underlying pharmacological patterns of antibiotic interactions, with potential applications in guidance in clinical therapies and in screening other cell-type agents.

17 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
SSSeverino Jefferson Ribeiro da Silva
Severino Jefferson Ribeiro da Silva
MSMohammad Simchi
Mohammad Simchi
QMQuinn Matthews
Quinn Matthews
PBPouriya Bayat
Pouriya Bayat
JVJustin R. J. Vigar
Justin R. J. Vigar
KPKeith Pardee
Keith Pardee
Recombinant proteins are fundamental to modern medicine, enabling research, diagnostics, and drug discovery, yet their access is often restricted by centralized manufacturing and cold-chain distribution. Decentralized, on-site biomanufacturing can enable research, provide resilience, and advance personalized medicine. Here, we introduce MANGO (MANufacturing on the GO), a purpose-built, open-source device designed for automated, benchtop cell-free protein synthesis and purification. Computer-controlled synthesis and purification are mediated through biomedical-grade pumps, valves, and a microchannel manifold, enabling rapid protein production directly at the point-of-use. To demonstrate MANGO’s utility, we produced and validated a diverse range of proteins, including nanobodies against SARS-CoV-2 and TNF, cloning enzymes, and diagnostic enzymes, with performance equivalent to their commercial counterparts. We further deployed MANGO in Brazil and Colombia to support patient trials for SARS-CoV-2 and dengue virus diagnostics. These results establish MANGO as a low-cost, portable platform that can democratize access to bioreagents in both high- and low-resource settings and, ultimately, expand participation in the bioeconomy.